Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of Monitoring
We report a case of monitoring the antibody response to the BioNTech–Pfizer vaccine of a 50-year-old female diagnosed with rheumatoid arthritis undergoing treatment with methotrexate (MTX). Antibody levels were measured 21 days after dose 1 (i.e., on the day of dose 2) and then 8, 14 and 30 days aft...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/10/1151 |
| _version_ | 1797513027882319872 |
|---|---|
| author | Krzysztof Lukaszuk Izabela Woclawek-Potocka Grzegorz Jakiel Paulina Malinowska Artur Wdowiak Karolina Rozanska Lukasz Rabalski |
| author_facet | Krzysztof Lukaszuk Izabela Woclawek-Potocka Grzegorz Jakiel Paulina Malinowska Artur Wdowiak Karolina Rozanska Lukasz Rabalski |
| author_sort | Krzysztof Lukaszuk |
| collection | DOAJ |
| description | We report a case of monitoring the antibody response to the BioNTech–Pfizer vaccine of a 50-year-old female diagnosed with rheumatoid arthritis undergoing treatment with methotrexate (MTX). Antibody levels were measured 21 days after dose 1 (i.e., on the day of dose 2) and then 8, 14 and 30 days after dose 2 with Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics). Patient showed a negative result after dose 1 and had the serum sample retested using a LIAISON<sup>®</sup> SARS-CoV-2 TrimericS IgG assay (DiaSorin), which showed a positive result. Subsequent samples were tested using both assays. Antibody levels kept increasing but at a much slower rate than in patients not receiving any immunomodulatory therapies. Other research indicates that among patients with autoimmune diseases, those receiving disease-modifying antirheumatic drugs (DMARDs) have higher COVID-19 mortality than those treated with tumor necrosis factor inhibitors (TNFis). These results indicate the need for people with autoimmune diseases to be carefully observed following vaccinations, including testing of antibody levels, and treated as potentially at risk until the effect of vaccination is confirmed. The different available vaccines should also be tested to verify their usefulness in the case of people with autoimmune diseases and those who take different immunomodulatory medications. |
| first_indexed | 2024-03-10T06:09:55Z |
| format | Article |
| id | doaj.art-ddd1242954be4acbb62a44a2950b47cd |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T06:09:55Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-ddd1242954be4acbb62a44a2950b47cd2023-11-22T20:15:59ZengMDPI AGVaccines2076-393X2021-10-01910115110.3390/vaccines9101151Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of MonitoringKrzysztof Lukaszuk0Izabela Woclawek-Potocka1Grzegorz Jakiel2Paulina Malinowska3Artur Wdowiak4Karolina Rozanska5Lukasz Rabalski6Department of Obstetrics and Gynecology Nursing, Medical University of Gdansk, 80-211 Gdansk, PolandDepartment of Gamete and Embryo Biology, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, 10-243 Olsztyn, PolandThe Center of Postgraduate Medical Education, 1st Department of Obstetrics and Gynecology, 01-004 Warsaw, PolandInvicta Research and Development Center, 81-740 Sopot, PolandDiagnostic Techniques Unit, Medical University of Lublin, 20-081 Lublin, PolandInvicta Research and Development Center, 81-740 Sopot, PolandLaboratory of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, 80-307 Gdansk, PolandWe report a case of monitoring the antibody response to the BioNTech–Pfizer vaccine of a 50-year-old female diagnosed with rheumatoid arthritis undergoing treatment with methotrexate (MTX). Antibody levels were measured 21 days after dose 1 (i.e., on the day of dose 2) and then 8, 14 and 30 days after dose 2 with Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics). Patient showed a negative result after dose 1 and had the serum sample retested using a LIAISON<sup>®</sup> SARS-CoV-2 TrimericS IgG assay (DiaSorin), which showed a positive result. Subsequent samples were tested using both assays. Antibody levels kept increasing but at a much slower rate than in patients not receiving any immunomodulatory therapies. Other research indicates that among patients with autoimmune diseases, those receiving disease-modifying antirheumatic drugs (DMARDs) have higher COVID-19 mortality than those treated with tumor necrosis factor inhibitors (TNFis). These results indicate the need for people with autoimmune diseases to be carefully observed following vaccinations, including testing of antibody levels, and treated as potentially at risk until the effect of vaccination is confirmed. The different available vaccines should also be tested to verify their usefulness in the case of people with autoimmune diseases and those who take different immunomodulatory medications.https://www.mdpi.com/2076-393X/9/10/1151COVID-19vaccinationmethotrexateTNFisautoimmune diseaseAIIRD |
| spellingShingle | Krzysztof Lukaszuk Izabela Woclawek-Potocka Grzegorz Jakiel Paulina Malinowska Artur Wdowiak Karolina Rozanska Lukasz Rabalski Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of Monitoring Vaccines COVID-19 vaccination methotrexate TNFis autoimmune disease AIIRD |
| title | Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of Monitoring |
| title_full | Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of Monitoring |
| title_fullStr | Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of Monitoring |
| title_full_unstemmed | Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of Monitoring |
| title_short | Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of Monitoring |
| title_sort | humoral response to sars cov 2 vaccine of a patient receiving methotrexate treatment and implications for the need of monitoring |
| topic | COVID-19 vaccination methotrexate TNFis autoimmune disease AIIRD |
| url | https://www.mdpi.com/2076-393X/9/10/1151 |
| work_keys_str_mv | AT krzysztoflukaszuk humoralresponsetosarscov2vaccineofapatientreceivingmethotrexatetreatmentandimplicationsfortheneedofmonitoring AT izabelawoclawekpotocka humoralresponsetosarscov2vaccineofapatientreceivingmethotrexatetreatmentandimplicationsfortheneedofmonitoring AT grzegorzjakiel humoralresponsetosarscov2vaccineofapatientreceivingmethotrexatetreatmentandimplicationsfortheneedofmonitoring AT paulinamalinowska humoralresponsetosarscov2vaccineofapatientreceivingmethotrexatetreatmentandimplicationsfortheneedofmonitoring AT arturwdowiak humoralresponsetosarscov2vaccineofapatientreceivingmethotrexatetreatmentandimplicationsfortheneedofmonitoring AT karolinarozanska humoralresponsetosarscov2vaccineofapatientreceivingmethotrexatetreatmentandimplicationsfortheneedofmonitoring AT lukaszrabalski humoralresponsetosarscov2vaccineofapatientreceivingmethotrexatetreatmentandimplicationsfortheneedofmonitoring |